GET DAILY SIGNALSUnmatched Trading Prowess: Tickeron's Top Robot Dominates with Over 70% Profitable Trades Amid Market Uncertainty!
Tickeron's quant team is thrilled to introduce the standout performer of the week, particularly noteworthy given the recent downturn in major stock indices. Despite the challenging market conditions, our quant team takes pride in highlighting the robot's exceptional achievement—delivering over 70% profitable signals for both long and short positions. This remarkable success can be attributed to its distinctive strategy, meticulously crafted to evaluate short-term trends in high-volatility stocks.
Swing Trader Pro: The Most Active Stocks with High Volatility (TA)
Click to view full description and closed trades for free!
Unleashing Precision Trading with Tickeron's AI Robot
Embark on a journey into the dynamic world of high-volatility stocks with our specially crafted AI Robot. Meticulously designed by Tickeron's expert quant team, this sophisticated algorithm blends classical and proprietary indicators to create a powerhouse for traders seeking maximum profitability.
Harnessing Mathematical Mastery for Daily Analysis
Our robot's mathematical prowess comes to life each day, meticulously analyzing short-term trends for individual stocks. The integration of machine learning algorithms ensures optimized parameters for each stock, enhancing the precision of trade signals and maximizing profits.
Strategic Trading Initiatives
Experience the agility of our robot as it strategically initiates trades based on signal strength. Depending on the quality of the signal, the robot can open multiple trades simultaneously, ensuring optimal profit extraction from the market's most effective signals.
Advanced Risk Management
Navigate the market with confidence through our advanced risk management system. A fixed limit take-profit order and a dynamic trailing stop algorithm work in tandem to safeguard your investments. The robot adapts in real-time to price dynamics, placing stop market orders strategically for optimal risk mitigation.
Here are the latest trades:
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EDIT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for EDIT turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 48 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
How Are Fiscal Quarters (Q1, Q2, Q3, Q4) Defined and Explained?
What is the Federal Savings and Loan Insurance Corporation (FSLIC)?
What is a Ponzi Scheme, and what are the key red flags that might indicate an investment is one?
How Do You Analyze Mid-Cap Stocks to Find the Investment 'Sweet Spot' ?
What is an Agent and How Do They Operate Across Different Domains?
General Information
a company which translates genome editing technology into a novel class of human therapeutics
Industry Biotechnology
Advertisement